- Fused tricyclic derivative as FGFR4 inhibitor
-
The present invention provides a fused tricyclic derivative that is the selective inhibitor of fibroblast growth factor receptor 4 (FGFR4), a pharmaceutical composition containing the compound, a method of making the compound and a method of treating cell proliferative diseases, such as cancer, using the compounds of the invention.
- -
-
Paragraph 0997-1002
(2021/05/12)
-
- 8-substituted styryl xanthine derivative and application thereof
-
The invention discloses an 8-substituted styryl xanthine derivative and application thereof, and particularly relates to a novel 8-substituted styryl xanthine derivative and a pharmaceutical composition containing the compound, and the 8-substituted styryl xanthine derivative can be used as a selective adenosine A2A receptor antagonist. The invention also relates to a method for preparing the compound and the pharmaceutical composition, and application of the compound and the pharmaceutical composition in preparation of drugs for treating adenosine A2A receptor related diseases, especially Parkinson's disease.
- -
-
Paragraph 0268; 0270-0272; 0338; 0340-0343
(2020/05/01)
-
- 2H-INDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE
-
This invention relates to 2H-indazole Derivatives of formula (I'), or pharmaceutically acceptable salts thereof, in which all of the variables are as defined in the specification, capable of modulating the activity of IRAK4. The invention further provides a method of manufacturing compounds of the invention, and methods for their therapeutic use. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including inflammatory disease, autoimmune disease, cancer, cardiovascular disease, a disease of the central nervous system, disease of the skin, an ophthalmic disease and condition, and a bone disease.
- -
-
Page/Page column 92
(2021/01/23)
-
- COMPOUNDS AND METHOD OF USE
-
This present disclosure relates to compounds with ferroptosis inducing activity, a method of treating a subject with cancer with the compounds, and combination treatments with a second therapeutic agent.
- -
-
Paragraph 1256
(2019/09/06)
-
- CYANO-SUBSTITUTED INDOLE COMPOUNDS AND USES THEREOF AS LSD1 INHIBITORS
-
A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for the treatment of lysine (K)-specific demethylase 1A (LSD1) - mediated diseases or disorders: (I) wherein R1, R2, R3, R4, R5, and R6 are as defined herein.
- -
-
Paragraph 00241
(2017/09/15)
-
- COMPOUNDS FOR BINDING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9)
-
The present disclosure relates to novel compounds, methods, and compositions capable of binding to PCSK9, thereby modulating PCSK9 proprotein convertase enzyme activity. The compounds of the disclosure include compounds Formula (I).
- -
-
Paragraph 0342
(2017/09/15)
-
- QUINAZOLINE HETEROCYCLIC COMPOUND AS EGFR KINASE INHIBITOR AND PREPARATION AND APPLICATION THEREOF
-
The present invention relates to an N-substituted-phenyl-5-substituted-alkoxy-2,3-dihydro-[1,4]dioxane[2,3-f]quinazolin-10-amine (I) or 4-substituted-arylamino-6-substituted-alkyl-6H-[1,4]oxazino[3,2-g]quinazoline-7(8H)-one (II) type compounds, a preparation method thereof and an application thereof as an inhibitor for epidermal growth factor receptor (EGFR) (comprising some mutant forms of EGFR) to treat cancer. These compounds and salts thereof can be used to treat or prevent various cancer diseases.
- -
-
Paragraph 0178; 0179
(2018/01/19)
-
- FUSED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTCIAL COMPOSITION, AND USES THEREOF
-
Disclosed are a fused heterocyclic compound, a preparation method therefor, a pharmaceutical composition, and uses thereof. The fused heterocyclic compound is shown in formula I, formula II, or formula III. The preparation method of the fused heterocyclic compound and/or the pharmaceutically acceptable salt thereof in the present invention comprises three synthesizing routes. The present invention also provides a pharmaceutical composition of the fused heterocyclic compound, the pharmaceutical composition containing one or more of the fused heterocyclic compound shown in formula I, formula II, or formula III, the pharmaceutically acceptable salt thereof, hydrates, solvent compounds, polymorphs and prodrugs thereof, and a pharmaceutically acceptable carrier. The present invention also relates to an application of the fused heterocyclic compound and/or the pharmaceutical composition in preparing kinase inhibitors and in preparing drugs for preventing and treating diseases related to kinase. The fused heterocyclic compound of the present invention has selective inhibition function on PI3Kδ, and can be used for preparing drugs for preventing and treating cell proliferation diseases such as cancers, infections, inflammations, or autoimmune diseases.
- -
-
Paragraph 0317; 0318; 0328; 0332
(2016/09/26)
-
- 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES
-
The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.
- -
-
Page/Page column 176
(2016/07/05)
-
- Enhanced treatment regimens using mTor inhibitors
-
The present invention provides for methods and pharmaceutical compositions comprising inhibitors of mTorC1 and/or mTorC2. In some aspects, the invention provides for treatment regimens resulting in enhanced treatment efficacy and better tolerability.
- -
-
Page/Page column 115; 116
(2015/11/27)
-
- NEW POSITIVE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTOR
-
The present invention relates to indole derivatives useful in therapy, to compositions comprising said compounds, and to methods of treating diseases comprising administration of said com- pounds. The compounds referred to are positive allosteric modulators (PAMs) of the nicotinic acetylcholine α7 receptor.
- -
-
Page/Page column 53
(2014/04/17)
-
- (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
-
Disclosed are (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles and their use as CB2 cannabinoid receptor agonists, pharmaceutical compositions containing the same, and their use for the treatment of CB2 receptor mediated disorders or conditions.
- -
-
Page/Page column 20
(2014/10/29)
-
- NOVEL (CYANO-DIMETHYL-METHYL)-ISOXAZOLES AND -[1,3,4]THIADIAZOLES
-
This invention relates to novel (Cyano-dimethyl-methyl)-isoxazolesand -[1,3,4]thiadiazoles and their use as CB2 cannabinoid receptor agonists, pharmaceutical compositions containing the same, and their use for the treatment of CB2 receptor mediated disorders or conditions.
- -
-
Page/Page column 22
(2014/12/12)
-
- COMBINATION OF KINASE INHIBITORS AND USES THEREOF
-
The present invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth. The present invention also provides a pharmaceutical kit effective for treating a disease condition associated with PI3 -kinase α and/or mTOR in a subject.
- -
-
Paragraph 00502
(2014/10/04)
-
- COMBINATION PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
-
The present invention provides for methods and pharmaceutical compositions for treating proliferative disorders. In one aspect, the method comprises administration of two cell-cycle suppressors having a synergistic effect. In another aspect, two cell-cycle suppressors having a synergistic effect are provided in a pharmaceutical composition.
- -
-
Paragraph 0485
(2014/12/09)
-
- SULFONYL COMPOUNDS WHICH MODULATE THE CB2 RECE
-
Compounds of formula (I) and formula (II) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are a
- -
-
Page/Page column 41-42
(2012/02/05)
-
- Pyrimidine compounds and methods of making and using same
-
Disclosed herein are pyrimidinyl compounds that are contemplated to be modulators of cystic fibrosis transmembrane regulators (CFTR), and methods of making and using same. Also provided are pharmaceutical compositions and methods of treating disorders associated with cystic fibrosis transmembrane regulators, such as airway inflammation, cystic fibrosis, and the like.
- -
-
Page/Page column 76-77
(2013/02/27)
-
- CARBOXYLIC ACID COMPOUND
-
[Problem] The present invention has an object to provide a compound having a GPR40 agonistic activity, which is useful as a pharmaceutical composition, an insulin secretion promoter, or an agent for preventing/treating diabetes. [Means for Solution] The present inventors have extensively studied a compound having a GPR40 agonistic activity, and as a result, they have found that the compound (I) of the present invention or a pharmaceutically acceptable salt thereof, in which a carboxylic acid is bonded to a bicyclic or tricyclic moiety through methylene, and further, a benzene ring substituted with a monocyclic 6-membered aromatic ring is bonded to a bicyclic or tricyclic moiety through —O-methylene or —NH-methylene, has an excellent GPR40 agonistic activity. They have also found that the compound has an excellent insulin secretion promoting action and strongly inhibits increase in the blood glucose after glucose loading, thereby completing the present invention.
- -
-
Page/Page column 28
(2012/02/15)
-
- Compounds Which Selectively Modulate The CB2 Receptor
-
Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.
- -
-
Page/Page column 18-19
(2011/04/18)
-
- COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR
-
Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally usefu
- -
-
Page/Page column 43-44
(2011/08/04)
-
- TETRAZOLE COMPOUNDS WHICH SELECTIVELY MODULATE THE CB2 RECEPTOR
-
Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally usefu
- -
-
Page/Page column 18
(2011/10/03)
-
- Compounds Which Selectively Modulate The CB2 Receptor
-
Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally usefu
- -
-
Page/Page column 35
(2010/04/23)
-
- SULFONE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR
-
Compounds which modulate the CB2 receptor are disclosed. Compounds according to the invention bind to and are agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating p
- -
-
Page/Page column 31
(2010/04/03)
-
- BENZOXAZOLE KINASE INHIBITORS AND METHODS OF USE
-
The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating certain protein kinases such as mTor, tyrosine kinases, and/or lipid kinases such as PI3 kinase. Also provided in the present invention are methods of using these compositions to modulate activities of one or more of these kinases, especially for therapeutic applications.
- -
-
Page/Page column 133
(2010/05/14)
-
- COMPOUNDS WHICH SELECTIVELY MODULATE THE CB2 RECEPTOR
-
Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.
- -
-
Page/Page column 74-75
(2010/12/31)
-
- THERAPEUTIC OR PROPHYLACTIC AGENT FOR LEUKEMIA
-
A therapeutic or prophylactic agent for leukemia is disclosed. The therapeutic or prophylactic agent comprises as an effective ingredient a glycine derivative having a specific structure or a pharmaceutically acceptable salt thereof, for example, the below-described compound [(E)-2-(2,6-dichlorobenzamido)-5-[4-(isopropyl-pyrimidin-2-ylamino)phenyl]pent-4-enoic acid]. The therapeutic or prophylactic agent for leukemia according to the present invention shows the excellent absorbability and in vivo stability when orally administered, and exhibits prominent therapeutic or prophylactic effects.
- -
-
Page/Page column 34
(2009/04/23)
-
- THERAPEUTIC OR PROPHYLACTIC AGENT FOR ALLERGIC DERMATITIS
-
A therapeutic or prophylactic agent for allergic dermatitis is disclosed. The therapeutic or prophylactic agent comprises as an effective ingredient a glycine derivative having a specific structure or a pharmaceutically acceptable salt thereof, for example, the below-described compound [(E)-2-(2,6-dichlorobenzamido)-5-[4-(isopropyl-pyrimidin-2-ylamino)phenyl]pent-4-enoic acid]. The therapeutic or prophylactic agent for allergic dermatitis according to the present invention has high therapeutic or prophylactic effect.
- -
-
Page/Page column 34
(2009/04/23)
-
- THERAPEUTIC OR PROPHYLACTIC AGENT FOR MULTIPLE SCLEROSIS
-
A therapeutic or prophylactic agent for multiple sclerosis is disclosed. The therapeutic or prophylactic agent comprises as an effective ingredient a glycine derivative having a specific structure or a pharmaceutically acceptable salt thereof, for example, the below-described compound [(E)-2-(2,6-dichlorobenzamido)-5-[4-(isopropyl-pyrimidin-2-ylamino)phenyl]pent-4-enoic acid]. The therapeutic or prophylactic agent for multiple sclerosis according to the present invention shows the excellent absorbability and in vivo stability when orally administered, and exhibits high therapeutic or prophylactic effects.
- -
-
Page/Page column 34
(2009/04/23)
-
- HETEROARYLCARBAMOYLBENZENE DERIVATIVES FOR THE TREATMENT OF DIABETES
-
Compounds of formula (I) wherein R1, R2, R3 and HET-1 are as described in the specification, and their salts, are activators of glucokinase (GLK) and are thereby useful in the treatment of, for example, type 2 diabetes. Processes for preparing compounds of formula (I) are also described.
- -
-
Page/Page column 45
(2010/11/25)
-
- INDOLE SULFONAMIDE MODULATORS OF PROGESTERONE RECEPTORS
-
Compounds of Formula (I), wherein n is 1 or 2, and R1, R2, R3, R4, R5, R6, R7, and R8 are as defined herein, their preparation, pharmaceutical compositions, and methods of use are disclosed.
- -
-
Page/Page column 56
(2008/06/13)
-
- GLYCINE DERIVATIVE AND USE THEREOF
-
A glycine derivative which is, e.g., the following compound (Chemical formula (1)). It is highly effective in the treatment and prevention of inflammatory bowel diseases. Compared to conventional compounds, the compound is excellent in absorbability in oral administration and in vivo stability. The compound can be orally administered and can retain an excellent therapeutic or preventive effect over a longer period.
- -
-
Page/Page column 53
(2008/06/13)
-
- Tetrahydropyran derivatives
-
A novel tetrahydropyran derivative which has an excellent apo B-related lipoprotein secretion-inhibiting activity of the following general formula (I) or a salt thereof: R8 and R9 are the same or different and each represents H, lower alkyl, R30-lower alkyl-, R31R32N-, optionally- substituted hetero ring, or R33R34R35C-; R8 and R9 may together form optionally-substituted hetero ring-; R30 represents optionally-substituted aryl, optionally-substituted hetero ring-, or lower alkyl-O-; R31 represents optionally-substituted aryl, or optionally-substituted hetero ring-; R33 represents HO-lower alkyl-, or optionally-substituted hetero ring-lower alkyl-; R34 represents optionally-substituted aryl-.
- -
-
-
- Piperidones as tachykinin antagonists
-
The present invention relates to a compound of the formula:- or a pharmaceutically acceptable acid addition salt or solvate thereof, wherein R is C3-C7 cycloalkyl, (C3-C7 cycloalkyl)C1-C4 alkylene or benzyl;R1 is phenyl optionally substituted by 1 or 2 su
- -
-
-
- Herbicidal 1-aryl-delta2-1,2,4-triazolin-5-ones
-
Aryltriazolinones of the formula STR1 in which W is oxygen or sulfur; X1 and X2 are independently selected from halogen, haloalkyl, and alkyl; R is a three- to eight-membered ring heterocyclic group of one or two, same or different, ring heteroatoms selected from oxygen, sulfur, and nitrogen, or an alkyl radical substituted with said heterocyclic group; R1 is alkyl, haloalkyl, cyanoalkyl, alkenyl, alkynyl, or a group of the formula -alkyl-Y--R3 ; R2 is halogen, alkyl, cyanoalkyl, haloalkyl, arylalkyl, or a group of the formula -alkyl-Y--R3 ; R3 is alkyl, alkenyl, or alkynyl; and Y is oxygen or S(O)r in which r is 0 to 2 are disclosed and exemplified.
- -
-
-